ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ブロモクリプチンメシル酸塩

Bromocriptine Mesylate

HCID 31100
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
22260-51-1
標準SMILES
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O
InChIKey
NOJMTMIRQRDZMT-GSPXQYRGSA-N
分子式
C33H44BrN5O8S
平均分子量
750.7 g/mol
単同位体質量
749.2094

概要

Bromocriptine methanesulfonate is a methanesulfonate salt. It has a role as an antiparkinson drug. It contains a bromocriptine.

名称と識別子

優先名称
Bromocriptine Mesylate
IUPAC
(6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
現地名
ブロモクリプチンメシル酸塩
英語名
Bromocriptine mesylate
分子式
C33H44BrN5O8S
分子量
750.7

名称と別名

BROMOCRIPTINE MESYLATE22260-51-1Bromocriptine mesilatePravidelCyclosetBagrenBromocriptine methanesulfonateCB-154 mesylateCb-154 mesilate2-Bromo-alpha-ergocryptine mesylateDTXSID6020197FFP983J3OD
名称をさらに表示
デパロエレナントパーロミンメシル酸ブロモクリプチンプロスペリンパルキゾンパドパリンパーロデル2-ブロモ-12'-ヒドロキシ-2'-(1-メチルエチル)-5'α-(2-メチルプロピル)エルゴタマン-3',6',18-トリオン·メタンスルホン酸パルロデルブロモクリプチンメタンスルホナートブロモクリプチンメシラートプラビデルブロモクリプチンメシル酸塩メーレーン2-ブロモ-12'-ヒドロキシ-2'-イソプロピル-5'α-(2-メチルプロピル)エルゴタマン-3',6',18-トリオン·メタンスルホン酸パロラクチンコーパデルアップノールBセロノ-バグレンBCTBRCBromocryptine mesylateBromocriptine-13C-d3 MesylateBromocriptine Mesylate (150 mg)cb-154Serono-Bagren
2-Bromoergocryptine MesylateNSC-755915DTXCID00197CHEBI:3182Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)-Mesylate, BromocriptineRefChem:564242 Bromoergocryptine Mesylate

物性

構造計算による物性

極性表面積
181 Ų
水素結合供与体数
4
水素結合受容体数
9
回転可能結合数
5
重原子数
48
形式電荷
0
複雑度
1,320

実験および物理化学的性質

Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Antiparkinson Agents; Dopamine Agonists; Ergot Alkaloids

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section244.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
192 · 192-196° (dec)
比旋光度
20 · D20 +95° (c = 1 in methanol-methylene chloride)
貯蔵温度
2 · 2-8°C
溶解性
2 O: · H2O: 0.8 mg/mL
外見
個体
酸解離定数(Pka)
4.9 · 4.90(at 25℃)
色
白い
水溶解度
2 O: · H2O: 0.8mg/mLethanol: 23mg/mL
Merck
13 · 13,1400
BRN
4115238 · 4115238
安定性
2 · 購入日から2年間安定です。この DMSO またはエタノール溶液は、-20°C で 3 か月間保存できます。
InChIKey
NOJMTMIRQRDZMT-JGYCFGIMSA-N
SMILES
N12[C@@H](CC(C)C)C(N3CCC[C@@]3([H])[C@]1(O)O[C@@](C(C)C)(NC(=O)[C@H]1CN(C3CC4=C(NC5C=CC=C(C4=5)C3=C1)Br)C)C2=O)=O.S(=O)(=O)(O)C |&1:1,11,13,16,23,r|

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (45.5%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P270, P271, P273, P280, P301+P317, P304+P340, P317, P318, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 11 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationBromocriptine mesylate: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'.alpha.)-, monomethanesulfonate (salt): Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (45.5%)

毒性情報

Treatment · 1 件

Treatment of overdose consists of removal of the drug by emesis (if conscious), gastric lavage, activated charcoal, or saline catharsis. Careful supervision and recording of fluid intake and output is essential. Hypotension should be treated by placing the patient in the Trendelenburg position and administering I.V. fluids. If satisfactory relief of hypotension cannot be achieved by using the above measures to their fullest extent, vasopressors should be considered. (L1827)

Health Effects · 1 件

A slight hypotensive effect may accompany bromocriptine treatment. Few cases of cerebrospinal fluid rhinorrhea have been reported in patients receiving bromocriptine for treatment of large prolactinomas. Bromocriptine use has been associated with causing or worsening psychotic symptoms and fibrosis of multiple organs. Ingestion of ergoline alkaloids is known to cause the disease ergotism. Ergotism occurs in two forms, gangrenous and convulsive, likely depending on the different kinds and amounts of ergoline alkaloids present. (A2913, L1827, L1934)

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Completely metabolized by the liver, primarily by hydrolysis of the amide bond to produce lysergic acid and a peptide fragment, both inactive and non-toxic. Bromocriptine is metabolized by cytochrome P450 3A4 and excreted primarily in the feces via biliary secretion. Route of Elimination: Parent drug and metabolites are almost completely excreted via the liver, and only 6% eliminated via the kidney. Half Life: 2-8 hours

FDA Pharmacological Classification · 2 件

BROMOCRIPTINE MESYLATE

Ergot Derivative [EPC]; Ergolines [CS]

MeSH Pharmacological Classification · 3 件

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.

Drugs that bind to and activate dopamine receptors.

用途と製造

Uses · 1 件

For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome. Bromocriptine is a semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion and is used in the treatment of pituitary tumors, Parkinson's disease (PD),Hyperprolactinaemia, neuroleptic malignant syndrome, and type 2 diabetes. Ergoline alkaloids occurs in various species of vines of the Convolvulaceae (morning glory) family and in some species of lower fungi. (L1918, L1934)

関連反応

1 件
反応記録を作成
HRID 729201 の反応式
HRID 729201反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
22260-51-1
PubChem CID
31100
DTXSID
DTXSID6020197
ChEMBL
CHEMBL1200503
ChEBI
CHEBI:3182
UNII
FFP983J3OD
EC Number
244-881-1
CAS データベース
22260 · 22260-51-1(CAS DataBase Reference)

化学的性質

化学的特性Solid

Exposure Routes · 1 件

Oral (L1934). Approximately 28% of the oral dose is absorbed; however due to a substantial first pass effect, only 6% of the oral dose reaches the systemic circulation unchanged. Bromocriptine and its metabolites appear in the blood as early as 10 minutes following oral administration and peak plasma concentration are reached within 1-1.5 hours. Serum prolactin may be decreased within 2 hours or oral administration with a maximal effect achieved after 8 hours. Growth hormone concentrations in patients with acromegaly is reduced within 1-2 hours with a single oral dose of 2.5 mg and decreased growth hormone concentrations persist for at least 4-5 hours.

Toxicity Summary · 1 件

The dopamine D<sub>2</sub> receptor is a 7-transmembrane G-protein coupled receptor associated with G<sub>i</sub> proteins. In lactotrophs, stimulation of dopamine D<sub>2</sub> receptor causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca<sup>2+</sup> from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D<sub>2</sub> receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Ergoline alkaloids have been shown to have the significant affinity towards the 5-HT1 and 5-HT2 serotonin receptors, D1 and D2 dopamine receptors, and alpha-adrenergic receptors. This can result in a number of different effects, including vasoconstriction, convulsions, and hallucinations. Bromocriptine acts by directly stimulating the dopamine receptors in the corpus striatum. (A2914, A2915, A2916, A2941)

Signs and Symptoms · 1 件

Side effects of bromocriptine include nausea, headache, dizziness, fatigue, lightheadedness, vomiting, abdominal cramps, nasal congestion, constipation, diarrhea and drowsiness. Convulsive ergotism can cause painful seizures and spasms, diarrhea, paresthesias, itching, headaches, nausea and vomiting. Usually the gastrointestinal effects precede the central nervous system effects. As well as seizures there can be hallucinations and mental effects including mania or psychosis. Gangrenous ergotism causes dry gangrene as a result of vasoconstriction induced in the more poorly vascularized distal structures, such as the fingers and toes. Symptoms include desquamation, weak periphery pulse, loss of peripheral sensation, edema and ultimately the death and loss of affected tissues. (L1920, L1827)

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Bromocriptine mesylate

vLess-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

F
3-10
wgk
3
rtecs
KE1595000
ridadr
UN 3077 9 / PGIII
毒性
LD50 in mice, rats, rabbits (mg/kg): 190, 72, 12.5 i.v. (Parkes)
hs_code
29396900
risk_code
20/21/22
hazard_code
Xn
safety_code
22-24/25-36
Hazard Classifications
Acute Tox. 4 OralAquatic Acute 1Aquatic Chronic 1
ストレージクラス
11 - Combustible Solids
応用分野 · 4 件

用途ドーパミンD2 レセプターの アゴニストです。

説明Bromocriptine is a dopamine receptor agonist (Kis = 1,659, 12.2, 12.2, 59.7, and 1,691 nM for dopamine D1, D2, D3, D4, and D5 receptors, respectively). It also binds to the serotonin (5-HT) receptor subtypes 5-HT1A and 5-HT1D (Kis = 12.9 and 10.7 nM, respectively), as well as α1-adrenergic receptors (Kis = 1.12-4.17 nM). Bromocriptine (5 mg/kg) restores locomotor activity, without inducing dyskinesia, in a macaque model of Parkinson’s disease induced by MPTP. Formulations containing bromocriptine have been used in the treatment of Parkinson''s disease, hyperprolactinemia-associated dysfunctions, and acromegaly.

使用Dopamine receptor agonist; derivative of the ergotoxin group of ergot alkaloids. Prolactin inhibitor; antiparkinsonian.

一般的な説明Bromocriptine mesylate,(6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate(Parlodel), is a white solid soluble in ethanol and slightly solublein water (pKa’s=6.6 and 15). Bromocriptine is rapidlyabsorbed after oral administration and it has low systemicbioavailability because of its extensive first-pass metabolism.Bromocriptine enters the brain quickly with a half-lifefor uptake into the brain of approximately 0.3 hours; 8% ofthe drug crosses the BBB.The metabolites are excreted primarilyin the bile and feces. The high first-pass hepatic metabolismimplies an increased risk of drug interactions.Concomitant administration with the DA antagonists, metoclopramide,or domperidone may aggravate parkinsoniansymptoms and induce extrapyramidal side effects (EPS).Other drugs that may interact with bromocriptine are highlyplasma protein–bound drugs (e.g., warfarin, increased dyskinesiacaused by bromocriptine); macrolides antibacterials(enhanced dopaminergic effects); and caffeine (elevation inplasma bromocriptine concentrations). The combination oflevodopa/AADC inhibitors with bromocriptine permits a reductionof the dose of levodopa. Thus, the side effects oflevodopa are decreased, resulting in a more continuous stimulationof DA receptors.

上流・下流製品情報

上流原料

12'-ヒドロキシ-2'-イソプロピル-5'α-イソブチルエルゴタマン-3',6',18-トリオンN-ブロモこはく酸イミド